本帖最后由 老马 于 2012-1-13 21:20 编辑
7 r3 E5 p, h- @& ], S4 }- n
' _" Z* H$ V8 o/ b6 n爱必妥和阿瓦斯丁的比较7 Q) ?4 P/ h8 A9 i' a
3 z; L/ T: s& t8 l/ Q k. O
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ E$ C4 {7 v% {( k# f
' h0 i: F* U' G7 V. p0 k1 n# k) K
7 X' z8 S9 x9 t" b) O
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
: D# x/ `2 e4 r% U9 Z3 M" i& W==================================================8 S7 t# _! ^) Y( U
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 y# s% @( O8 X" {- a) QPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
j* G3 `6 p6 ~8 Q2 ]' W8 M6 PResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.7 C5 T" R b0 O# f7 C( m/ _) e
|